
Compugen Ltd. — Investor Relations & Filings
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Compugen to Release First Quarter 2026 Results on May 18, 2026 will host a conference call at 8:30 AM ET | 2026-05-04 | English | |
| Compugen to Release First Quarter 2026 Results on May 18, 2026 will host a conference call at 8:30 AM ET | 2026-05-04 | English | |
| Other Report or Announcement | 2026-04-28 | English | |
| Other Report or Announcement | 2026-04-28 | English | |
| Other Report or Announcement | 2026-04-28 | English | |
| Other Report or Announcement | 2026-04-28 | English |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Whitehawk Therapeutics, Inc.
A preclinical oncology company developing advanced antibody…
|
WHWK | US | Professional, scientific and te… |
|
WOOJUNG BIO, Inc.
Offers pre-clinical CRO services, research facility enginee…
|
215380 | KR | Professional, scientific and te… |
|
WuXi AppTec Co., Ltd.
Global CRDMO enabling pharma and life sciences to accelerat…
|
2359 | CN | Professional, scientific and te… |
|
Xceleron Inc.
Specialist provider of ultra-sensitive bioanalytical servic…
|
— | CA | Professional, scientific and te… |
|
XEROS TECHNOLOGY GROUP PLC
Develops and licenses polymer-based solutions that reduce i…
|
XSG | GB | Professional, scientific and te… |
|
Xilio Therapeutics, Inc.
A clinical-stage biotech developing tumor-activated immuno-…
|
XLO | US | Professional, scientific and te… |
|
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD
Pharmaceutical R&D and CRO services for drug discovery and …
|
600721 | CN | Professional, scientific and te… |
|
Xintela AB
Biomedical company developing stem cell therapies for regen…
|
XINT | SE | Professional, scientific and te… |
|
Xlife Sciences AG
Develops and commercializes early-stage life sciences resea…
|
XLS | CH | Professional, scientific and te… |
|
XtalPi Holdings Limited
Accelerates molecular R&D using AI, quantum physics, and ro…
|
2228 | KY | Professional, scientific and te… |
Compugen Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/6734/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=6734 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=6734 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=6734 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 6734}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Compugen Ltd. (id: 6734)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.